DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical

Executive Summary

• DiagnosTear Technologies Inc. entered into a non‑binding Letter of Intent with Hanson Instruments Ltd. (trading as Hanson Medical) to exclusively explore commercialization of the TeaRx™ dry‑eye diagnostic platform in the United Kingdom through May 15, 2026.
• The LOI establishes a framework for market evaluation, clinical integration studies, pricing and distribution discussions, with the goal of negotiating a definitive commercial agreement if results are favorable.
• The partnership is positioned as a strategic step to expand DiagnosTear’s European footprint and accelerate adoption of its CE‑IVD‑approved point‑of‑care ocular diagnostic solution.

Key Details

• Parties: DiagnosTear Technologies Inc. (CSE: DTR) and Hanson Instruments Ltd., operating as Hanson Medical, a UK‑based supplier of ophthalmic and optometric equipment.
• Scope: Exclusive exploration of commercial opportunities for the TeaRx™ platform in the United Kingdom during the LOI Period (now through 15 May 2026).
• Objectives of LOI:
• Conduct market evaluation activities across the UK.
• Engage eye‑care professionals to assess clinical integration, demand, and adoption pathways.
• Define potential distribution responsibilities, pricing structures, and clinical engagement programs.
• Potential Outcome: If both parties are satisfied with the LOI results, they may enter into a definitive commercial agreement covering distribution and commercialization of TeaRx™ in the UK.
• Product Highlight: TeaRx™ is a CE‑IVD‑approved rapid diagnostic system that analyzes tear fluid at point‑of‑care to provide objective data for dry‑eye disease diagnosis and management.
• Strategic Rationale (CEO Quote): “The United Kingdom is a sophisticated ophthalmic market with strong clinical infrastructure and early adoption of innovative diagnostic technologies… Working with an established local partner such as Hanson Medical allows us to assess real‑world workflow integration while laying the groundwork for long‑term market development.” – Dr. Shimon Gross, CEO, DiagnosTear.
• Forward‑Looking Statements: The release contains forward‑looking information regarding global commercialization strategy, expected UK adoption of TeaRx™, and potential negotiation of a definitive agreement after the LOI period.

Notable Quotes

“The United Kingdom is a sophisticated ophthalmic market with strong clinical infrastructure and early adoption of innovative diagnostic technologies,” said Dr. Shimon Gross, Chief Executive Officer of DiagnosTear. “Working with an established local partner such as Hanson Medical allows us to assess real‑world workflow integration while laying the groundwork for long‑term market development.”